{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:30:41Z","timestamp":1780381841152,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00774-019-01052-6","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T11:04:33Z","timestamp":1572519873000},"page":"254-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma"],"prefix":"10.1007","volume":"38","author":[{"given":"Ha-Lim","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Hee","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyowon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"1052_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"1052_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"1052_CR3","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00520-013-1887-3","volume":"21","author":"G Oster","year":"2013","unstructured":"Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21:3279\u20133286 (Official Journal of the Multinational Association of Supportive Care in Cancer)","journal-title":"Support Care Cancer"},{"key":"1052_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","volume":"16","author":"L Costa","year":"2008","unstructured":"Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence. Support Care Cancer 16:879\u2013889 (Official Journal of the Multinational Association of Supportive Care in Cancer)","journal-title":"Support Care Cancer"},{"key":"1052_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000082923","volume":"67","author":"T Delea","year":"2004","unstructured":"Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G (2004) The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67:390\u2013396","journal-title":"Oncology"},{"key":"1052_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","volume":"80","author":"MJ Rogers","year":"1997","unstructured":"Rogers MJ, Watts DJ, Russell RG (1997) Overview of bisphosphonates. Cancer 80:1652\u20131660","journal-title":"Cancer"},{"key":"1052_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/ctrv.1999.0133","volume":"25","author":"T Yoneda","year":"1999","unstructured":"Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (1999) Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 25:293\u2013299","journal-title":"Cancer Treat Rev"},{"key":"1052_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","volume":"5","author":"RE Coleman","year":"2000","unstructured":"Coleman RE (2000) Management of bone metastases. Oncologist 5:463\u2013470","journal-title":"Oncologist"},{"key":"1052_CR9","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321 (Official Journal of the American Society of Clinical Oncology)","journal-title":"J Clin Oncol"},{"key":"1052_CR10","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J (Sudbury, Mass) 7:377\u2013387","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"1052_CR11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"1052_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"1052_CR13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150\u20133157 (Official journal of the American Society of Clinical Oncology)","journal-title":"J Clin Oncol"},{"key":"1052_CR14","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/cncr.23775","volume":"113","author":"HT Hatoum","year":"2008","unstructured":"Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 113:1438\u20131445","journal-title":"Cancer"},{"key":"1052_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","volume":"11","author":"HT Hatoum","year":"2011","unstructured":"Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A (2011) Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer 11:177\u2013183","journal-title":"Clin Breast Cancer"},{"key":"1052_CR16","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller RD, Jemal A (2016) Cancer statistics. CA 66:7\u201330 (A Cancer Journal For Clinicians","journal-title":"CA"},{"key":"1052_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4143\/crt.2015.060","volume":"47","author":"KW Jung","year":"2015","unstructured":"Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, Lee KH (2015) Cancer Statistics in Korea: incidence, Mortality, Survival, and Prevalence in 2012. Cancer Res Treat 47:127\u2013141 (Official Journal of Korean Cancer Association)","journal-title":"Cancer Res Treat"},{"key":"1052_CR18","first-page":"e15","volume":"46","author":"J Lee","year":"2017","unstructured":"Lee J, Lee JS, Park SH, Shin SA, Kim K (2017) Cohort Profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol 46:e15","journal-title":"Int J Epidemiol"},{"key":"1052_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132 (Official Journal of the American Society of Clinical Oncology)","journal-title":"J Clin Oncol"},{"key":"1052_CR20","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (Lond, Engl) 376:1989\u20131999","journal-title":"Lancet (Lond, Engl)"},{"key":"1052_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492\u2013499","journal-title":"Am J Epidemiol"},{"key":"1052_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2407-11-29","volume":"11","author":"AO Jensen","year":"2011","unstructured":"Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29","journal-title":"BMC Cancer"},{"key":"1052_CR23","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Lash TL (2008) Modern epidemiology. Lippincott Williams and Wilkins, Philadelphia"},{"key":"1052_CR24","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139 (Official journal of the American Society of Clinical Oncology)","journal-title":"J Clin Oncol"},{"key":"1052_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (Lond, Engl) 377:813\u2013822","journal-title":"Lancet (Lond, Engl)"},{"key":"1052_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139","journal-title":"Med Care"},{"key":"1052_CR27","doi-asserted-by":"publisher","first-page":"e98043","DOI":"10.1371\/journal.pone.0098043","volume":"9","author":"HA Kim","year":"2014","unstructured":"Kim HA, Shin JY, Kim MH, Park BJ (2014) Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 9:e98043","journal-title":"PLoS One"},{"key":"1052_CR28","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporosis 25:2359\u20132381 (International: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA)","journal-title":"Osteoporosis"},{"key":"1052_CR29","unstructured":"Parsons LS (2001) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the twenty-sixth Annual SAS users group international conference 2001: SAS Institute Inc."},{"key":"1052_CR30","volume-title":"A unified approach to measuring the effect size between two groups using SAS","author":"K Yang","year":"2012","unstructured":"Yang K, Dalton JE (2012) A unified approach to measuring the effect size between two groups using SAS. SAS Global Forum, Washington"},{"key":"1052_CR31","volume-title":"DeVita, Hellman, and Rosenberg\u2019s cancer: principles and practice of oncology review","author":"R Govindan","year":"2009","unstructured":"Govindan R, DeVita VT (2009) DeVita, Hellman, and Rosenberg\u2019s cancer: principles and practice of oncology review. Lippincott Williams and Wilkins, Philadelphia"},{"key":"1052_CR32","unstructured":"National Comprehensive Cancer Network (NCCN) (2018) NCCN Guidelines for Breast Cancer. \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n\n. Accessed 10 Apr 2018"},{"key":"1052_CR33","unstructured":"National Comprehensive Cancer Network (NCCN) (2018) NCCN Guidelines for Prostate Cancer. \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf\n\n. Accessed 10 Apr 2018"},{"key":"1052_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","volume":"61","author":"YH Baek","year":"2019","unstructured":"Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY (2019) Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol 61:104\u2013110","journal-title":"Cancer Epidemiol"},{"key":"1052_CR35","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1097\/CCM.0b013e3181b7fbbb","volume":"37","author":"AK Shintani","year":"2009","unstructured":"Shintani AK, Girard TD, Arbogast PG, Moons KGM, Ely EW (2009) Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 37:2939\u20132945","journal-title":"Crit Care Med"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01052-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-019-01052-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-01052-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T01:26:35Z","timestamp":1604021195000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-019-01052-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s00774-019-01052-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Shin received grant support to her institution from Amgen. Hyowon Yang and Jeehye Park are employees of Amgen Limited Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}